Clinical Trial Detail

NCT ID NCT02575300
Title Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

pancreatic endocrine carcinoma

Therapies

Ibrutinib

Age Groups: adult

No variant requirements are available.